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Robot-assisted laparoscopic prostatectomy (RALP) is a potentially curative surgical 
intervention for men with clinically localized prostate cancer. Although RALP can provide 
excellent oncological outcomes, it is also associated with detrimental effects to functional 
outcomes, particularly urinary continence, which negatively impact post-operative 
quality of life. The purpose of this study is to identify the degree to which pre-operative 
patient factors, tumor characteristics, and surgical technique influenced the post-
operative return of urinary continence in men undergoing RALP performed by a single 
surgeon for the treatment of clinically localized prostate cancer. We analyzed 182 
consecutive patients with clinically localized prostate cancer who were treated with RALP 
between April 2013 and September 2020. A retrospective chart review was performed to 
evaluate pre-operative patient and tumor characteristics, as well as post-operative 
urinary continence. Achievement of urinary continence was defined as wearing no pads 
or an occasional security pad by patient-reported daily pad usage within 3 (early) and 12 
months (late) after RALP. Postoperatively, 68 (37.3%) and 120 (78.9%) men achieved early 
and late recovery of continence, respectively.  Multivariate logistic regression analyses 
revealed that Retzius sparing approach (OR 2.995; 95% CI 1.265 – 7.089; p = 0.013) and 
lower BMI (OR 0.823; 95% CI 0.823 – 0.988; p = 0.027) were associated with continence 
at 3 months post-operatively, while longer pre-operative membranous urethral length 
(OR 1.205; 95% CI 1.003 – 1.448; p = 0.047) and younger age (OR 0.907; 95% CI 0.824 – 
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Prostate Cancer: Epidemiology and Treatment 
Prostate cancer continues to be the most common non-skin malignancy and the 
second-leading cause of cancer deaths among men in the United States. There will be an 
estimated 191,930 new cases diagnosed in 2020, representing 21% of new cancer cases 
in men, and over 33,000 deaths [1]. Fortunately, the majority of cases are slow-growing 
and low grade with limited aggressiveness. Consequently, the overall 5-year survival rate 
in the United States is greater than 98%, and the lifetime risk of death from prostate 
cancer is less than 3% [2]. The true prevalence of prostate cancer is likely substantially 
higher than reported based on evidence from autopsy studies [3, 4].  
The primary risk factors for developing prostate cancer are age, race, and family 
history of the disease. It is primarily a disease of older men, with 99% of all prostate 
cancers occurring in men over the age of 50. Incidence is also known to be associated with 
hereditary and geographic factors previously described as ‘race.’ In the United States, the 
rate of new cases per 100,00 in 2017 was 163.8, 96.7, 80.9, and 54.9 among White, Black, 
Hispanic, and Asian/Pacific Islander men, respectively [5]. Other risk factors include 
obesity, hypertension, elevated testosterone levels, and certain environmental 
exposures. 
In recent decades, an increasing number of cases have been diagnosed at earlier 
clinical stages, due primarily to the widespread adoption of prostate-specific antigen 




treatment counseling. First, a larger proportion of newly diagnosed tumors are confined 
to the prostate, making them more amenable to localized therapies aimed at removing 
malignant tissue. Second, a greater number of young, otherwise healthy men are 
receiving the diagnosis of prostate cancer. This population may have different goals and 
expectations regarding post-operative quality of life outcomes, namely the preservation 
of urinary and erectile function, compared to the older cohort of the pre-PSA era. 
Patients with localized prostate cancer (clinical stage T1-T2, N0 or NX, M0 or MX) 
are stratified into risk categories to guide treatment decisions based on clinical stage, PSA, 
Grade Group, amount of cancer on biopsy (i.e., number of cores involved, maximum 
involvement of any single core), PSA density, and diagnostic imaging. Current primary 
treatment modalities include active surveillance (PSA testing, digital rectal exams, 
surveillance biopsies), external beam radiation therapy (RT), ablative procedures 
(cryoablation, high-intensity ultrasound, etc.), and radical prostatectomy (RP). According 
to current AUA guidelines, Level A evidence (strong recommendation) supports the use 
of RP for patients with intermediate- to high-risk disease. Level B evidence (conditional 
recommendation) supports its use in low-risk disease in patients who have a high 
probability of progression on active surveillance, though clinicians should recommend 
active surveillance for most low-risk localized prostate cancer patients. These conclusions 
are based on three notable prospective randomized controlled trials investigating the 
long-term mortality and functional outcomes after RP compared to other interventions.  
The Scandinavian Prostate Cancer Study Group number 4 (SPCG-4) randomized 




1989 and 1999. The study found a reduced risk of all-cause and prostate cancer-specific 
death, a lower rate of prostate cancer metastasis, and less use of palliative androgen-
deprivation therapy in the RP group after a median follow-up time of 13.4 years. These 
effects were more pronounced among men younger than 65 years and in those with 
intermediate-risk tumors [7]. By contrast, the Prostate Cancer Intervention Versus 
Observation Trial (PIVOT), which randomized 731 men to treatment with RP or 
observation between 1994 and 2002, found no significant differences in all-cause and 
prostate cancer-mortality between groups at ten years of follow up. On sub-group 
analysis, the PIVOT study found a possible survival benefit to RP in men with intermediate 
and high-risk tumors only [8]. The generalizability of these studies is limited, however, 
because they were conducted either completely or partially before the era of PSA 
screening. Therefore, the cohorts are likely to be poorly representative of the relatively 
healthier contemporary population of men diagnosed with prostate cancer. 
A third study, the Prostate Testing for Cancer and Treatment (ProtecT) trial, 
compared the long-term oncologic outcomes associated with radiotherapy, surgery, and 
active surveillance among men diagnosed with PSA-detected prostate cancer.  In this 
study, 82,429 men 50 to 69 years of age were randomized to one of the three treatment 
arms between 1999 and 2009, with a primary outcome of prostate cancer-specific 
mortality at a median of 10 years follow-up. While the authors reported that surgery and 
radiotherapy can reduce the risk of cancer progression and metastasis, they found no 




the 10-year median follow-up [9]. These initial findings suggest that there may be minimal 
benefit to treating prostate cancer within the first decade after diagnosis. 
However, longer follow up studies in the SPCG-4 [10] and PIVOT [11] trials have 
since revealed oncologic benefits associated with the surgical treatment of prostate 
cancer. At a median follow-up time of 23 years, the authors of the SPCG-4 study 
reaffirmed that the prostatectomy group had significantly lower rates of overall and 
prostate cancer-specific mortality, as well as a lower risk of metastasis, when compared 
to the watchful waiting group. At this longer follow-up time, the absolute benefit 
associated with surgery increased by a factor of more than 2 for overall and prostate 
cancer-specific mortality. In the PIVOT trial, surgery was associated with lower all-cause 
mortality among the 249 patients with intermediate-risk disease at a median follow-up 
time of 19.5 years (HR = 0.68. 95% CI: 0.50-0.92). This benefit to surgery was not found in 
low- and high- risk groups at this time-point. Given the time delay between surgery and 
oncologic outcome improvements, men with longer life expectancies are likely to benefit 
the most from prostatectomy. It is therefore essential to consider the impact of this 





Incontinence after Treatment of Prostate Cancer 
It is well documented that each of the common primary therapies for localized 
prostate cancer can detrimentally affect functional outcomes with a negative impact on 
patient quality of life, including bowel, sexual, and urinary function. Persistent urinary 
incontinence has an especially profound negative impact on patient quality of life, causing 
emotional distress and restrictions to normal physical activity [12, 13]. As such, current 
AUA guidelines stress the importance of treatment counseling that incorporates shared 
decision making and considers patient goals and preferences as well as tumor 
characteristics [14]. 
Despite an increasing understanding of the etiology of post-prostatectomy 
incontinence and improvements in surgical technique, incontinence rates are still 
substantial and vary widely between different studies [15]. The variation in reported 
continence outcomes stems, in part, from the lack of standardization in the definition of 
continence. The most common definition of continence in the literature is patient-
reported use of 0 urinary pads per day (ppd) or a single safety liner, while others have 
favored a stricter definition of absolutely no pad usage. A common method to further 
quantify the degree of urinary incontinence is to document the number of pads used per 
day. However, several studies have brought the validity of this approach into question, 
showing that patients may change their pads at different rates based on their individual 
attitudes and preferences rather than the actual volume of urine leakage [16, 17]. 
Measurement of pad weight to more accurately assess urine leakage has been employed 




standardized questionnaires, such as the International Continence Society Male Short-
Form (ICSmaleSF) questionnaire [18, 19], the Expanded Prostate Cancer Index Composite 
(EPIC) instrument [20, 21], the International Consultation on Incontinence Questionnaire 
(ICIQ) [22, 23], and International Prostate Symptom Score (IPSS) [24] are commonly used 
to evaluate urinary function and impact on quality of life. 
Data on patient-reported functional outcomes from the ProtecT trial, which 
incorporated both measurements of pad count and some of the validated questionnaires 
listed above, demonstrated that RP had a greater negative effect on urinary continence 
than RT and active surveillance [25]. By year 6 of the study, 17% of men in the RP group 
were using pads, compared to 8% in the active-monitoring group and 4% in the RT group. 
The impact of urinary continence on quality of life was worse in the RP group for 2 years, 
and subsequently became comparable to the other groups. In addition, a large, 
population-based analysis reported that 6% of men treated with RP had undergone at 
least 1 procedure to treat post-prostatectomy incontinence, such as urethral sling or 





The Evolution of the Radical Prostatectomy 
First performed over a century ago, the RP was traditionally performed via an 
open, retropubic approach [27]. Over time, several innovations have been developed to 
improve outcomes toward the RP “trifecta”: resection of malignant tissue with negative 
surgical margins, preservation of urinary continence, and avoidance of erectile 
dysfunction [28].  
The introduction of the Da Vinci surgical system in 2001 prompted a shift from the 
open RP to a robot-assisted laparoscopic approach (RALP). The enhanced visual field and 
seven-degree motion provided by the robotic instruments offered the advantage of 
precise identification of the fascial layers surrounding the prostate. This technology was 
rapidly adopted despite the absence of conclusive evidence supporting its superiority at 
the time, and as of 2015, nearly 70% of radical prostatectomies were performed 
robotically in the United States [29]. In the past two decades, studies comparing the two 
approaches have generally concluded that RALP leads to better peri-operative and long-
term functional outcomes, without compromising oncological outcomes. 
Guazzoni et al. [30] performed a prospective, randomized, single-surgeon study 
comparing intra- and peri-operative outcomes between open RP and laparoscopic RP 
(LRP), concluding that LRP offers the potential advantages of reduced blood loss, safe 
early catheter removal, and possibly lower rates of analgesic use. The authors reported 
no difference in post-operative complications and positive surgical margins (PSM) 
between groups. In a randomized controlled trial (RCT) comparing early outcomes in 326 




in oncologic outcomes (positive surgical margin rate) or post-operative complications, nor 
did they detect any significant differences in urinary and sexual function outcomes 
between the groups at 6- and 12-weeks post-surgery. Two-year results from the same 
cohort [32] confirmed the similar functional outcomes between groups, as determined 
by the urinary and sexual domains of the EPIC questionnaire. 
Results from three meta-analyses [33-35] comparing RALP and open RP found that 
the robotic approach had better intra- and peri-operative outcomes, including estimated 
blood loss (EBL), transfusion rates, overall complication rate, and duration of hospital 
stay. Neither Cao et al. [35] nor Basiri et al. [34] found significant differences in oncological 
or functional outcomes at time points of up to 24 months. Tang et al. [33] found higher 
12- month rates of erectile function recovery after RALP (OR: 2.37, p = 0.005) compared 
to open RP, but failed to find a significant difference with respect to urinary continence. 
A more recent innovation to the surgical treatment of prostate cancer is the 
Retzius sparing approach to RALP (RS-RALP), which preserves several structures thought 
to play a role in urinary continence. First described by Galfano et al. in 2010, this approach 
passes through the pouch of Douglas, following an intrafascial plane and avoiding 
dissection of the anterior compartment, which contains endopelvic fascia, neurovascular 
bundles, puboprostatic ligaments, and the prostatic venous plexus [36]. Dissection of the 
bladder neck proceeds in a posterior-to-anterior fashion, preserving the integrity of the 
detrusor apron at the bladder neck.  
An early report of the first 200 patients to undergo RS-RALP demonstrated 




removal, 90-92% of patients were continent, defined as no pads or one safety liner per 
day. At 1-year follow-up, the continence rate reached 100%. The patients in this cohort 
were primarily low to intermediate risk (96% with Gleason score ≤ 7), with relatively small 
prostates (median prostate volume 43 mL, interquartile range 28-58 mL). Finally, while 
89-92% of patients achieved biochemical disease-free survival at one-year follow-up, the 
authors note that the overall PSM rate was 25.5%.  
Two randomized, single surgeon trials comparing RS-RALP and the standard 
approach suggested that RS-RALP may provide superior short-term continence outcomes 
[38, 39]. Menon et al. randomized 120 patients with clinically low-intermediate risk 
disease to RS-RALP or traditional RALP. While the authors demonstrated significantly 
higher rates of continence in the RS-RALP group at 3 months, these differences were 
muted by 1 year after surgery. The PSM rate was noted to be higher in the RS-RALP group, 
though the difference was not significant (11.7% vs. 8.3%, p > 0.05). Asimakopoulos et al. 
also showed superior continence outcomes (defined as 0 ppd, no safety liner) in the RS-
RALP group up to 6 months after surgery, but longer-term data was not available. More 
recently, Qiu et al. [40] performed a randomized, controlled, single-blind study 
demonstrating higher rates of immediate continence (pad-free within 1 week after 
catheter removal) in the RS-RALP group compared to traditional RALP (69.1% vs. 30.9%, 
p = 0.000). Continence outcomes were also better in the RS-RALP group at 1 year (HR= 
1.51, log-rank p = 0.007), though on sub-group analysis this applied only to patients with 
low-intermediate risk disease. Oncologic outcomes, including PSM rate, were comparable 




Taken together, these studies provide initial evidence that RS-RALP provides 
swifter return of continence compared to the traditional approach, but further studies 
are needed to determine whether these differences remain significant at time points up 
to a year after surgery. They also highlight the importance of appropriate selection of 
patients for this procedure, given that there is some evidence of higher PSM rates with 
this technique, particularly in higher risk patients. This potential drawback of RS-RALP 
follows directly from its 360° intrafascial dissection of the prostate, which preserves key 
surrounding structures as described above but also risks incomplete tumor resection, 
particularly in cases where the tumor is located peripherally in the gland. 
Another aspect of the surgical technique to consider is preservation of the 
neurovascular bundle (NVB). Walsh et al. first described the posterolateral location of the 
NVB relative to the prostate, its relevance to erectile function, and the nerve sparing (NS) 
technique to improve post-operative erectile function [41, 42]. The relevance of NS 
approach to preservation of urinary continence has subsequently been recognized [43]. 
Michl et al. provided insight into the possible mechanism of improved long-term 
continence rates with NS RP [44]. They retrospectively analyzed patients who underwent 
NS and non-nerve sparing (NNS) procedures, as well as a third group who had a secondary 
resection of the NVBs for positive frozen-section results after initial NS dissection 
(secNNS). Interestingly, they demonstrated increased post-operative continence rates at 
1 week, 3 months, and 1 year both among patients in the NS and secNNS groups 
compared to the NNS group. Continence rates at 1 year did not differ significantly 




that the meticulous apical dissection involved in the NS approach, and not the actual 
preservation of the NVBs, accounted for the improved continence outcomes in this group.   
 
Patient Characteristics Influencing Return of Continence 
Previous studies have found that certain pre-operative patient characteristics also 
influence post-operative return of continence, including age, body mass index (BMI), 
comorbidity index, membranous urethral length (MUL), prostate volume, and lower 
urinary tract symptoms (LUTS) [15, 45]. 
Several studies have examined the effect of age on functional outcomes after 
radical prostatectomy. In a large retrospective study, Mandel et al. [46] stratified patients 
who underwent open RP or RALP into age groups of <65, ≥65 and <70, ≥70 and <75, and 
≥75, and showed that continence outcomes (defined as 0-1 ppd) at 3 months (80.3%, 
74.0%, 70.3%, and 66.1%, p < 0.001) and 1 year (93.3%, 90.8%, 86.0%, and 86.5%, p < 
0.001) after surgery decreased significantly with increasing age at the time of surgery. It 
is interesting to note that, although there was a significant difference across age groups 
in continence rates at both time points, the difference narrowed at 1 year, suggesting that 
older men who ultimately achieve continence may simply take longer to do so. Similarly, 
Kundu et al. [47] found significant differences in rates of return of continence (defined as 
no pads) for patients aged <50, 50-59, 60-69, and ≥70 years (95%, 96%, 93%, and 86%, 
respectively, p < 0.001) among men who underwent open RP. In contrast, Kunz et al. [48] 




between patients aged <70 (n = 1,225) and ≥70 (n = 411), using ICSmaleSF questionnaire 
scores to quantify the degree of continence. 
Studies including only RALP procedures have also yielded mixed results with 
respect to the effect of age on continence. Shikanov et al. [49] demonstrated a significant 
influence of age on the probability of achieving continence at 12 months (OR = 0.97, p = 
0.002) among 1,436 men who underwent RALP. Basto et al. [50] stratified 262 men who 
underwent RALP into two groups (age <70 and ≥70 years). While they found a trend 
toward fewer older men being fully continent (no pads) at 4-6 weeks, there were no 
differences between the groups beyond 3 months. Similarly, Greco et al. [51] performed 
a single-surgeon retrospective analysis of men who underwent RALP and found that 
continence (no pads) was significantly lower in men ≥70 years at 6 months after surgery 
but returned to levels equivalent to those in younger men by 1 year. Finally, in a larger 
study of 2,000 RALP patients, Labanaris et al. [52] did not find a significant difference in 
the 12-month continence rate (no pads) between groups aged <75 and ≥75 years (92.8% 
vs. 86.9%, p > 0.05). 
Membranous urethral length (MUL), the distance from the prostatic apex to the 
level of the urethra at the penile bulb, has also been reported to affect post-
prostatectomy return of continence. This value can be measured pre-operatively on T2-
weighted magnetic resonance imaging (MRI) images. A meta-analysis of studies 
examining this anatomical factor concluded that MUL had a significant positive effect on 
the odds of continence recovery at 3-, 6-, and 12-months following surgery [53]. The 




continence recovery increased by 5-15% (OR: 1.09, 95% CI:1.05-1.15; p < 0.001). A recent 
retrospective study by Ikarashi et al. examined the effect of MUL on continence recovery 
after RALP [54]. The authors estimated a cutoff point for using MUL to predict return of 
continence at 3 months after surgery using a receiver operating characteristic (ROC) 
analysis. They found that using a cutoff point of 12 mm MUL could predict continence at 
3 months with 80% sensitivity and 70% specificity. 
Prostate volume (or weight) is another anatomical characteristic that may affect 
continence outcomes, although conflicting evidence exists in the literature. Mandel et al. 
performed a retrospective study of 5,477 patients who underwent RP and found that 
large prostate volume (>70 mL) negatively impacted post-operative return of continence, 
particularly at early (1-week and 3-month) time points [55]. Several other investigators 
have found similar results regarding the impact of prostate volume on post-operative 
continence, both in patients receiving open RP and RALP [56-58]. More recently, Galfano 
et al. investigated the effect of prostate volume on continence specifically after RS-RALP 
[59]. They evaluated 750 patients with small (<40 g), medium (40-60 g), and large (>60 g) 
prostates who underwent RS-RALP and found significant differences in the immediate 
continence rate between groups (88%, 89.5%, 81.3%; p = 0.045). However, no differences 






The purpose of this study is to identify the degree to which pre-operative patient 
factors, tumor characteristics, and surgical technique influenced the post-operative 
return of urinary continence in men undergoing RALP performed by a single surgeon for 








Between April 2013 and September 2020, 182 men undergoing robotic-assisted 
laparoscopic prostatectomy (RALP) by a single urologist for clinically localized or locally 
advanced prostate cancer at our institution (Yale-New Haven Hospital) were included in 
the final analysis, after exclusion criteria were applied. 
 
Surgical Procedure and Pathology 
RALP was performed using the multiple- or single-port da Vinci surgical robot 
system (Intuitive Surgical, Sunnyvale, CA) via a transperitoneal or extraperitoneal 
approach. Information on the details of the surgical technique were recorded, namely the 
presence of pelvic lymph node dissection (PLND), complete or partial nerve sparing, and 
Retzius sparing approach. Patients without contraindications underwent pelvic MRI pre-
operatively. Pathological staging, Gleason score, Grade Group, presence of metastatic 
lymph nodes, and prostate weight were determined by a board-certified pathologist from 
whole mount surgical specimens. and retrospectively documented based on pathology 
reports. 
 
Evaluation of Pre-operative Patient Characteristics and Surgical Approach 
 Age at the time of surgery, body mass index (BMI), type of surgical approach 




retrospectively collected from patient charts. Prostate volume was estimated on pre-
operative pelvic MRI by a board-certified radiologist and extracted from image reports. 
MUL was retrospectively measured on T2-weighted coronal and sagittal sections as the 
distance from the prostatic apex to the level of the urethra at the penile bulb on pre-
operative pelvic MRI. Measurements from the coronal and sagittal sections were 
averaged for the final estimate of MUL. 
 
Evaluation of Post-operative Urinary Continence 
Post-operative recovery of urinary continence was defined as patient-reported 
use of 0 ppd or an occasional safety liner, as documented in notes from routine post-
operative clinic visits. Achievement of continence was defined as early if it occurred within 
3 months, and late if it occurred within 12 months after the date of surgery. Catheter 
removal occurred one week after the date of surgery in most cases. Two patients in our 
cohort required prolonged catheterization longer than one week due to post-operative 
complications (1 urine leak, 1 urinary fistula). Patients who underwent salvage RT were 
excluded from our analysis starting at the date of RT initiation.  
 
Statistical Methods 
Kruskal–Wallis test was used for statistical analysis of proportions, and the Mann-
Whitney U test was used for continuous variables. Univariable and multivariable logistic 
regression and ROC curves were used to assess discriminatory ability of membranous 




were statistically significant. SPSS version 27 (IBM SPSS Statistics, Armonk, NY, USA) was 







Patient Characteristics and Surgical Approach 
We identified a total of 187 patients who underwent radical prostatectomy for the 
treatment of clinically localized or locally advanced prostate cancer, performed by a single 
surgeon at our institution between 2013 and 2020. Four patients were excluded from our 
analysis because the surgical procedure was performed via an open retropubic approach, 
rather than RALP. Thirty-one patients underwent salvage RT within one year after surgery 
and were therefore excluded from our analysis at the 12-month timepoint to avoid 
confounding effects on continence outcomes from radiation exposure. One patient 
underwent RT within three months after surgery and was therefore excluded from both 
the 3- and 12-month timepoints. The remaining 30 patients who underwent RT between 
3 and 12 months were excluded from the 12-month analysis. The final number of included 
patients was therefore 182 at the 3-month timepoint, and 152 at the 12-month timepoint. 
Clinical characteristics of the patients included in the study, as well as details on the 
surgical approach used, are shown in Table 1. Mean patient age was 62.4 ± 6.4 years, 
mean BMI was 28.6 ± 4.4 kg/m2, mean pre-operative PSA was 11.8 ± 16.7 ng/mL, mean 
prostate weight was 49.4 ± 25.5 g, and mean MUL was 13.7 ± 3.4 mm. All patients included 
in our analysis were continent prior to surgery. All patients included in our analysis 
underwent RALP with bilateral pelvic lymph node dissection (BPLND). 57 (31%) patients 
underwent a complete nerve sparing procedure, 79 (43%) patients underwent a partial 




Retzius sparing was performed in 43 (24%) patients, and a single port procedure was 









Age (years)     
  Mean ± SD 62.4 ± 6.4 
  Min - Max 41.2 - 76.7 
  No. (%) <60 55 (30%) 
  No. (%) ≥60 and <65 53 (29%) 
 No. (%) ≥65 and <70 50 (28%) 
 No. (%) ≥70 24 (13%) 
BMI (kg/m²)     
  Mean ± SD 28.6 ± 4.4 
  Min - Max 20.1 - 44.9 
Pathological Stage    
  No. (%) Stage II 78 (43%) 
  No. (%) Stage III 95 (40%) 
 No. (%) Stage IV 31 (17%) 
Grade Group (Surgical Pathology)    
  No. (%) GG 1 3 (2%) 
  No. (%) GG 2 109 (60%) 
 No. (%) GG 3 49 (27%) 
  No. (%) GG ≥4 19 (10%) 
 No. (%) Unassigned1 2 (1%) 
Pre-operative PSA (ng/mL)    
 Mean ± SD 11.8 ± 16.7  
 Min - Max 0.1 - 137 
Prostate weight (g)    
  Mean ± SD 49.4 ± 25.5 
  Min-Max 14 - 182 
MUL (average)    
  Mean ± SD 13.7 ± 3.4 
  Min-Max 6.4 - 23.3 
Surgical 
approach 
Non-nerve sparing No. (%) 46 (25%) 
Partial nerve sparing No. (%) 79 (43%) 
Complete nerve sparing No. (%) 57 (31%) 
Non-Retzius sparing No. (%) 139 (76%) 
Retzius sparing No. (%) 43 (24%) 
Single Port No. (%) 11 (6%) 
1By convention, a Gleason score is not assigned to patients who received androgen deprivation therapy 





Early Recovery of Continence 
Early recovery of urinary continence, defined as continence at 3 months after 
surgery, was achieved in 68 (37.4%) patients. In the univariate analysis for early recovery 
of continence, lower BMI (27.6 kg/m2 vs. 29.1 kg/m2, p = 0.014), lower prostate weight 
(43.0 g vs. 52.0 g, p = 0.003), and the Retzius sparing approach (60.9% vs. 29.3%, p < 0.001) 
were significantly associated with continence at this timepoint. Results from the 
multivariate analysis for early recovery of continence are shown in Table 2. BMI (OR 0.902 
per kg/m2; 95% CI 0.823 – 0.988; p = 0.027) and Retzius sparing surgery (OR 2.995; 95% 
CI 1.265 – 7.089; p = 0.013) were shown to be significantly and independently associated 
with continence by 3 months. Prostate weight (OR 0.992; 95% CI 0.971 – 1.013; p = 0.436) 





Table 2. Multivariate analysis results for the early (3-month) recovery of urinary 
continence. Significant values are denoted in bold. 
 
Variable p value Odds Ratio (OR) 95% C.I. for OR 
Age (years) 0.159 0.955 0.897 – 1.018 
BMI (kg/m2) 0.027* 0.902 0.823 – 0.988 
Prostate weight (g) 0.436 0.992 0.971 – 1.013 
MUL (mm) 0.094 1.110 0.982 – 1.255 
Non-nerve Sparing (ref) 0.614  
Unilateral nerve sparing 0.327 1.724 0.581 – 5.117 
Bilateral nerve sparing 0.422 1.606 0.506 – 5.097 
Retzius sparing 0.013* 2.995 1.265 – 7.089 
 
Late Recovery of Continence 
Late recovery of urinary continence, defined as continence at 12 months after 
surgery, was achieved in 120 (78.9%) patients. In the univariate analysis, younger age at 
the time of surgery (61.7 years vs. 65.0 years, p = 0.004) was significantly associated with 
continence at this time point. The 12-month continence rates for age groups < 60, ≥ 60 
and < 65, ≥ 65 and < 70, and ≥ 70 years were 89.3%, 73.8%, 66.0%, and 66.7%, respectively 
(p = 0.053). On multivariate analysis, MUL (OR 1.205 per mm; 95% CI 1.003 – 1.448; p = 




were shown to be significantly and independently associated with continence at 12 
months post-operatively. Results from the analysis are shown in Table 3.  
As previously noted, 30 patients included in the 3-month analysis were 
subsequently excluded at this timepoint due to initiation of salvage radiotherapy within 
1 year after surgery. Among this subset of patients, 20 (66.7%) achieved continence prior 
to the initiation of radiotherapy. Furthermore, a total of 22 (73.3%) of these patients 
achieved continence within a year after RALP. 
 
Table 3. Multivariate analysis for the late (12-month) recovery of urinary continence. 
Significant values are denoted in bold. 
 
Variable p value Odds Ratio (OR) 95% C.I. for OR 
Age (years) 0.044* 0.907 0.824 – 0.998 
BMI (kg/m2) 0.381 1.057 0.933 – 1.198 
Prostate weight (g) 0.225 0.985 0.960 – 1.010 
MUL (mm) 0.047* 1.205 1.003 – 1.448 
Non-nerve Sparing (ref) 0.128  
Unilateral nerve sparing 0.321 0.540 0.160 – 1.824 
Bilateral nerve sparing 0.384 1.876 0.455 – 7.741 






The receiver operating characteristic (ROC) curve for MUL measurement as a 
predictor of continence at 12 months is shown in Figure 1. The area under the curve (AUC) 
was 0.60. We identified a reasonable cutoff point of MUL > 10.6 mm for recovery of 
continence at 12 months using the ROC analysis. Using this cutoff point, we were able to 
predict continence at 12 months after RALP with a sensitivity of 85% and a specificity of 
43%.  
 






 This study demonstrates that early recovery of continence after RALP is primarily 
associated with lower BMI and Retzius sparing approach, while younger age and longer 
pre-operative MUL are the strongest predictors of the return of continence at 12 months 
post-operatively. The overall rates of continence recovery for the patients in this cohort 
were 37.3% at 3 months and 78.9% at 12 months. As previously noted, post-operative 
continence rates vary widely in the literature. The 2012 meta-analysis performed by 
Ficarra et al. [15] reported 12-month continence rates ranging from 69% to 96%, with a 
mean value of 84% using a no pad definition. Considering a no pad or safety pad 
definition, as was done in this study, the authors noted a narrower range of 89% to 92%, 
with a mean value of 91% at 12 months.  
The Retzius sparing approach was strongly associated with continence at the 3-
month timepoint, however this association disappeared at the 12-month timepoint. This 
result is in line with data from a number of similar studies, including the Menon et al. 
study [38] cited previously, which also found a significant effect at 3 months that was 
subsequently muted by 12 months post-operatively. In our study at 3 months, the overall 
continence rate among patients who underwent RS-RALP was 60.9% versus 29.3% among 
those who underwent conventional RALP. Menon et al. achieved a 3-month continence 
rate of 95% with the Retzius sparing approach versus 86% with conventional RALP. These 
remarkably high values may be partially explained by their cohort, which consisted of 




cohort, and also surgeon experience. Nevertheless, our results highlight the relative 
efficacy of the Retzius sparing approach with respect to achieving earlier restoration of 
continence, without necessarily affecting long term outcomes. As previously discussed, 
the mechanistic explanation for earlier continence using this approach is related to better 
preservation of the bladder neck and structures in the space of Retzius. Further studies 
with larger scale cohorts are needed to definitively show whether the advantage of this 
approach truly does not extend past the first 3 to 6 months after surgery. 
Similarly, lower BMI was also predictive of higher rates of continence at 3 months 
after RALP, but this effect was not seen at 1 year post-operatively. This finding is 
consistent with a 2015 study by Matsushita et al. [60] that examined 2,849 radical 
prostatectomies to identify predictors of continence. The authors reported that BMI was 
associated with urinary continence at 6 months (OR 0.97; p = 0.01), but not at 12 months 
(p = 0.1). As noted previously, Mandel et al. [46] performed a large study on over 8,000 
patients who underwent radical prostatectomy. They showed that BMI was significantly 
associated with urinary continence at both 3 months (OR 0.97; 95% CI 0.94 – 0.99; p = 
0.002) and 12 months (OR 0.96; 95% CI 0.94 – 0.99; p = 0.013). 
When considering the results of our study at 3 versus 12 months after RALP, it 
should be noted that the later timepoint carried somewhat less power than the earlier 
timepoint due to our exclusion criteria, which included initiation of salvage radiotherapy. 
Because we excluded patients from our analysis at the time of salvage therapy initiation, 
30 patients were excluded from the 12-month analysis after undergoing radiation 




attrition partially explains the loss of the significant associations of BMI and RS-RALP with 
continence between the two timepoints. Among this subset, 20 (66.7%) achieved 
continence prior to the initiation of salvage radiotherapy, and 22 (73.3%) were continent 
within a year after surgery. Therefore, while not included in the final analysis, the 
continence rates in this subset were similar to the larger cohort. 
Our analysis showed that younger age was significantly associated with higher 
rates of continence at one year after RALP. However, this association was not seen at 3 
months. There was a trend toward increasing continence rates at 12 months across age 
groups < 60, ≥ 60 and < 65, ≥ 65 and < 70, and ≥ 70 years (89.3%, 73.8%, 66.0%, and 66.7%; 
p = 0.053). As discussed previously, Mandel et al. [46] also found that continence rates 
decreased significantly with increasing age. The 12-month continence rates for age 
groups < 65, ≥ 65 and < 70, ≥ 70 and < 75, and ≥ 75 years were 93.2%, 90.8%, 86.0%, and 
86.5%, respectively. It should be noted that this study’s cohort was slightly older than 
ours (mean age 63.9 years), it stratified patients into different age groups than our study, 
and it included both open and robotic prostatectomies. 
Our results also agree with the Shikanov et al. study [49], which included only 
robotic procedures. They found that increasing age was associated with decreasing 1-year 
continence rates (OR 0.92; p < 0.0001), which closely matched our results. However, their 
overall continence rates were somewhat lower due to their use of a stricter (no pad) 
definition of continence. Interestingly, both Basto et al. [50] and Greco et al. [51] found 
that younger age was associated with higher continence rates at earlier time points, but 




with differences in continence between age groups becoming significant only at the 12-
month timepoint. 
Longer pre-operative MUL was also shown to be predictive of continence at 12 
months after surgery, with an OR of 1.205 per millimeter (p=0.047). As previously noted, 
the meta-analysis conducted by Mungovan et al. [53] yielded similar results. The authors 
examined 11 studies that reported the OR for restoration of continence at one or more 
time points and found that MUL had a significantly positive effect on continence at 12 
months (OR: 1.12, 95% CI: 1.03–1.22, p = 0.006). In contrast to our results, they also found 
significant associations of a similar magnitude between MUL and continence at 3 and 6 
months. Similarly, the Ikarashi et al. study [54] found a significant association between 
MUL and lower rates of incontinence at 3 (OR 0.635; 95% CI 0.53 – 0.74; p < 0.0001), 6 
(OR 0.699; 95% CI 0.56 – 0.85; p = 0.0002), and 12 (OR 0.743; 95% CI 0.56 – 0.96; p = 
0.026) months.  
This association is thought to stem from the coordinated function of the smooth 
muscle fibers within the membranous urethra and the rhabdosphincter that surrounds it, 
which plays a key role in preventing urinary leakage. Increased MUL is therefore related 
to a greater number of these muscular components that increase urethral closure 
pressure that aid in recovery of continence. Paparel et al. [61] showed this with pre- and 
post-operative measurements of MUL, showing that decreased length of MUL after 
surgery also predicts incontinence. The authors also suggested that limiting intra-




decreased elasticity of the external urinary sphincter, is important to the preservation of 
continence. 
After establishing the association between MUL and the late recovery of 
continence, we constructed an ROC curve to evaluate the predictive ability of this 
measurement and identify a reasonable cutoff point for favorable prediction of 
continence at 12 months after RALP. The results of the ROC analysis yielded a proposed 
cutoff point of 11 mm, which predicted 12-month recovery of continence with 85% 
sensitivity. However, the specificity was considerably lower at 43%, which limits its utility 
as an accurate predictive tool. Comparing these results to the Ikarashi et al. study [54], 
the authors identified a cutoff point of 12 mm for continence at 3 months, yielding an 
80% sensitivity and 70% specificity. 
There are several limitations which may have influenced the validity of this study’s 
results. First, the retrospective design of the study introduced several sources of bias. 
Most notably, some patient records were missing or incomplete, especially with respect 
to consistent documentation of patient pad count in post-operative clinic notes. A 
prospective study with a standardized method of collecting pad count data or the use of 
a validated incontinence questionnaire would be a more reliable method of evaluating 
urinary continence outcomes. Furthermore, even among patients with complete records, 
self-reported pad count is an inherently imperfect measure of incontinence due to recall 
bias, different activity levels between patients requiring different needs for protection 
against urinary leakage, and different patient preferences with respect to their tolerance 




limitation of the study is its relatively small size (N=182), which limits the study’s power. 
Finally, the study’s single-surgeon design may limit the ability to generalize the results to 
the entire population of men undergoing RALP. 
In summary, these results add to the existing literature examining the factors, 
related to both pre-operative patient characteristics and surgical technique, that affect 
the probability of a patient recovering urinary continence in their first year after RALP. 
Identifying the relative importance of these influences on continence is critical to the 
appropriate counseling of patients considering their treatment options for prostate 
cancer. An understanding of the primary risk factors for post-operative incontinence 
presented here and elsewhere in the literature, combined with a firm understanding of 
each patient’s specific goals and expectations, will allow physicians to provide better 
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